Bell Investment Advisors’s Denali Therapeutics DNLI Stock Holding History

Bell Investment Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$978	Hold	38	–	–	﹤0.01%	1535
2026 Q1	$730	Hold	38	–	–	﹤0.01%	1625
2025 Q4	$628	Sell	38 -21	-36%	-$354	﹤0.01%	1667
2025 Q3	$857	Sell	59 -64	-52%	-$920	﹤0.01%	1596
2025 Q2	$1.72K	Buy	123 +71	+137%	+$999	﹤0.01%	1406
2025 Q1	$707	Hold	52	–	–	﹤0.01%	1656
2024 Q4	$1.06K	Hold	52	–	–	﹤0.01%	1561
2024 Q3	$1.51K	Hold	52	–	–	﹤0.01%	1457
2024 Q2	$1.21K	Hold	52	–	–	﹤0.01%	1553
2024 Q1	$1.07K	Sell	52 -25	-32%	-$470	﹤0.01%	1586
2023 Q4	$1.65K	Buy	77 +34	+79%	+$673	﹤0.01%	1413
2023 Q3	$888	Sell	43 -21	-33%	-$533	﹤0.01%	1614
2023 Q2	$1.89K	Hold	64	–	–	﹤0.01%	1329
2023 Q1	$1.48K	Hold	64	–	–	﹤0.01%	1406
2022 Q4	$1.78K	Hold	64	–	–	﹤0.01%	1352
2022 Q3	$2K	Hold	64	–	–	﹤0.01%	1080
2022 Q2	$2K	Buy	+64	New	+$1.68K	﹤0.01%	1127
2021 Q4	$0	Sell	11 -13	-54%	-$616	﹤0.01%	1814
2021 Q3	$1K	Buy	+24	New	+$1.35K	﹤0.01%	1345

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bell Investment Advisors's DNLI Position: Q2 2026 in Review

Bell Investment Advisors held its Denali Therapeutics (DNLI) position steady in Q2 2026 at 38 shares worth $978. The position accounts for ﹤0.01% of the portfolio, ranked #1535.

Bell Investment Advisors first reported a position in DNLI in Q3 2021 and has held it in 19 quarters since. The position peaked at $2K in Q3 2022. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Bell Investment Advisors held 38 shares of Denali Therapeutics worth $978 as of Q2 2026.
Bell Investment Advisors left its Denali Therapeutics share count unchanged in Q2 2026.
Denali Therapeutics made up ﹤0.01% of Bell Investment Advisors's portfolio in Q2 2026, its #1535 holding.
Bell Investment Advisors first reported a position in Denali Therapeutics in Q3 2021 and has held it in 19 quarters since.
Bell Investment Advisors's Denali Therapeutics position peaked at $2K in Q3 2022.
292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.